Please assess the completion status of the following clinical trial:

Trial Title: 3T Endorectal Magnetic Resonance Spectroscopic Imaging (MRSI) of Prostate

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Newly diagnosed biopsy proven prostate carcinoma who are referred to Diagnostic Imaging for magnetic resonance imaging (MRI) / magnetic resonance spectroscopic imaging (MRSI)~2. No previous radiation to prostate or pelvis~3. No hormonal treatment for prostate~4. The interval between the biopsy and magnetic resonance spectroscopic imaging (MRSI): more than 6 weeks~5. Informed consent~Exclusion Criteria:~1. Contraindications for MRI (e.g. cardiac pacemaker)~2. Allergy to Latex~3. Contraindications for magnetic resonance spectroscopic imaging (MRSI) (e.g. history of abdomino-perineal resection of rectum)~4. Metals or any conditions (e.g. hip prosthesis) that can distort the local magnetic field~5. Previous prostate surgery for prostate carcinoma (including, transurethral resection of the prostate (TURP) and cryosurgery), local or systemic treatment for prostate carcinoma (e.g. radiation, androgen deprivation), pelvic radiation (e.g. rectal cancer), rectal surgery, BCG for bladder cancer~6. Children (\<18 years)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AIR-MRSI (Type: EXPERIMENTAL): Endorectal MRSI with Air
- PFC-MRSI (Type: EXPERIMENTAL): Endorectal MRSI with PFC

Based on this trial design, predict the completion outcome and termination type (if applicable).